Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.
暂无分享,去创建一个
R. Berkowitz | S. Mok | W. Welch | W. Chan | K. Cheung | J. Schorge | D. Bell | L. W. Huang | W Y Chan | W R Welch | K K Cheung | R S Berkowitz | S C Mok | J O Schorge | L W Huang | D A Bell | L. W. Huang | L. Huang | W. Chan | Ross S. Berkowitz | Kwok Kuen Cheung | Lee Wen Huang | William R. Welch | Debra A. Bell | Samuel C. Mok | K. Cheung
[1] C. Angeletti,et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.
[2] F. Gruijl,et al. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. , 1997, Archives of dermatology.
[3] J C Reed,et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.
[4] S. Korsmeyer,et al. bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. , 1994, Development.
[5] J. Lee,et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. , 1995, Cancer research.
[6] S. Hirohashi,et al. High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy , 1992, Japanese journal of cancer research : Gann.
[7] John Calvin Reed. Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.
[8] G. Elia,et al. Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinoma , 1993, International journal of cancer.
[9] S. Cannistra. Medical progress : cancer of the ovary , 1993 .
[10] R. Berkowitz,et al. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.
[11] A. Villanueva,et al. K‐ras mutations in mucinous ovarian tumors , 1997, Cancer.
[12] P. Sevelda,et al. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. , 1995, Gynecologic oncology.
[13] G. Tortolero-Luna,et al. The epidemiology of ovarian cancer , 1995, Journal of cellular biochemistry. Supplement.
[14] R. Knapp,et al. Unifocal origin of advanced human epithelial ovarian cancers. , 1992, Cancer research.
[15] H. Hartung,et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[16] M. Itabashi,et al. Expression of Bcl‐2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis , 1997, Pathology international.
[17] C. Croce,et al. DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Goldblum,et al. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis , 1999, American Journal of Gastroenterology.
[19] R. Berkowitz,et al. p53 gene mutation in human borderline epithelial ovarian tumors. , 1994, Journal of the National Cancer Institute.
[20] M. Clarke,et al. Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. , 1998, Molecular genetics and metabolism.
[21] Yi-Song Wang,et al. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. , 1993, Oncogene.
[22] R. Bast,et al. Molecular approaches to prevention and detection of epithelial ovarian cancer , 1995, Journal of cellular biochemistry. Supplement.
[23] G. Baretton,et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. , 1996, American journal of clinical pathology.
[24] John Calvin Reed,et al. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.
[25] L. Verburgt,et al. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. , 1996, American journal of respiratory cell and molecular biology.
[26] S. Korsmeyer,et al. Bcl-2 protein expression during murine development. , 1994, The American journal of pathology.
[27] S. Grénman,et al. Immunohistochemically detected p53 and HER‐2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas , 1997, Cancer.
[28] Medicine,et al. Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.
[29] N. Harris,et al. Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma. , 1996, American journal of clinical pathology.
[30] A. Baldini,et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer , 1998, Oncogene.
[31] John Calvin Reed,et al. Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.
[32] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[33] S. Syrjänen,et al. Implications of the p53 tumor-suppressor gene in clinical oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Louis,et al. Human gliomas with wild-type p53 express bcl-2. , 1995, Cancer research.
[35] M. Campbell,et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.
[36] P. Shaw,et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[37] A. Jochemsen,et al. Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis. , 1995, Carcinogenesis.
[38] R. Berkowitz,et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. , 1993, Cancer research.
[39] A. Okamoto,et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. , 1991, Cancer research.
[40] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[41] M. Rugge,et al. bcl‐2 and p53 immunophenotypes in pre‐invasive, early and advanced oesophageal squamous cancer , 1997, Histopathology.
[42] A. Kimchi,et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.
[43] C. Potten,et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. , 1996, British Journal of Cancer.
[44] R. Warnke,et al. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. , 1993, The American journal of pathology.
[45] D. Easton,et al. Contribution of BRCA1 mutations to ovarian cancer. , 1997, The New England journal of medicine.
[46] C. Kittas,et al. Immunohistochemical detection of p53 protein in HPV positive oral lesions. , 1998, Anticancer research.
[47] Y. Homma,et al. Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. , 1997, The Journal of urology.
[48] L. Donehower,et al. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. , 1994, Oncogene.
[49] M. Karpeh,et al. Immunohistochemical evaluation of bcl‐2 protein expression in gastric adenocarcinomas , 1995, Cancer.
[50] C. Croce,et al. Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.
[51] A. Wyllie,et al. The genetic regulation of apoptosis. , 1995, Current opinion in genetics & development.
[52] W. Chan,et al. Apoptosis and Bcl‐2 oncoprotein expression in the human fetal central nervous system , 1998, The Anatomical record.
[53] P. Lipponen,et al. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis , 1994, The Journal of pathology.
[54] E. Wilander,et al. Expression and prognostic significance of Bcl-2 in ovarian tumours. , 1995, British Journal of Cancer.
[55] S. Thorgeirsson,et al. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] S. Korsmeyer,et al. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[57] J. Boyd,et al. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. , 1996, Gynecologic oncology.
[58] B. Vogelstein,et al. Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.
[59] A. Harris,et al. bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.
[60] M. Higashiyama,et al. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. , 1995, Anticancer research.
[61] H. Kitchener,et al. p53 mutation is a common genetic event in ovarian carcinoma. , 1993, Cancer research.